Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
In a survey, analysts found that reimbursement and test awareness were major barriers to driving adoption of the firm's assay for identifying skin cancer.
The company plans to use the net proceeds for working capital, to improve its platform and tests, as well as to expand internationally and acquire assets.
The administration has proposed steps such as funding increased production of testing supplies and ensuring schools have access to more frequent testing.
